['plaque psoriasis']
['arq-151 cream 0.3%', 'arq-151 cream 0.15%', 'arq-151 vehicle cream']

        Inclusion Criteria:

          -  Participants legally competent to sign and give informed consent

          -  Males and females ages 18 years and older (inclusive)

          -  Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined
             by the Investigator

          -  Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at
             Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must
             agree to use at least one form of highly effective contraception throughout the trial.

          -  In good health as judged by the Investigator, based on medical history, physical
             examination, serum chemistry labs, hematology values, and urinalysis.

          -  Subjects are considered reliable and capable of adhering to the Protocol and visit
             schedule, according to the judgment of the Investigator.

        Exclusion Criteria:

          -  Planned excessive exposure of treated area(s) to either natural or artificial sunlight
             or tanning bed.

          -  Females who are pregnant, wishing to become pregnant during the study, or are
             breast-feeding.

          -  Previous treatment with ARQ-151 or its active ingredient

          -  Subjects with any serious medical condition or laboratory abnormality that would
             prevent study participation or place the subject at significant risk, as determined by
             the Investigator.

          -  Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation
             of study medication.

          -  Subjects who are unable to communicate, read or understand the local language, or who
             display another condition, which in the Investigator's opinion, makes them unsuitable
             for clinical study participation.
      